Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies Coronavirus COVID-19 Vaccines

Coronavirus Update: White House Picks Five Vaccines For US Operation Warp Speed

Fauci Cautiously Optimistic About 2020 Goal

Executive Summary

An official announcement is expected within weeks, as competition between US and China stokes fears of 'vaccine nationalism'. 

You may also be interested in...



Moderna’s COVID-19 Vaccine Spurs Immune Response In All Phase I Subjects At All Doses

Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Coronavirus Update: GSK Stresses Need For Broad Vaccines Amid Future Pandemic Risk

Also, Neoimmune looks to interleukin therapy for mild therapy while Daiichi Sankyo bets on a mRNA vaccine.

Table

View full table

Related Content

Scrip
Pink Sheet
Scrip
Pink Sheet
Scrip
Scrip

Topics

Related Companies

Tags:
Companies Coronavirus COVID-19 Vaccines
Latest Headlines

China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public

Quick Listen: Scrip's Five Must-Know Things

AbbVie Exits CAR-T Cell Therapy Development Partnership With Caribou

Blueprint’s Evolution On Its Path To Financial Sustainability

See All
UsernamePublicRestriction

Register

SC142346

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By